BRIEF published on 09/18/2024 at 07:05, 1 year 6 months ago Relief Therapeutics achève la phase clinique de l'étude RLF-OD032 Étude Clinique RLF-OD032 Biodisponibilité Phénylcétonurie Dichlorhydrate De Saproptérine
BRIEF published on 09/18/2024 at 07:05, 1 year 6 months ago Relief Therapeutics Completes Clinical Phase of RLF-OD032 Study Clinical Study Bioavailability RLF-OD032 Phenylketonuria Sapropterin Dihydrochloride
PRESS RELEASE published on 09/18/2024 at 07:00, 1 year 6 months ago Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024 Relief Therapeutics completes clinical phase in RLF-OD032 proof-of-concept study for PKU treatment, expecting topline results in October 2024 Relief Therapeutics RLF-OD032 Proof-of-Concept Study PKU Treatment Topline Results
BRIEF published on 09/02/2024 at 07:05, 1 year 6 months ago Relief Therapeutics annonce la présentation des résultats de l'étude PKU GOLIKE au SSIEM 2024 Essai Clinique PKU GOLIKE THÉRAPEUTIQUE DE SECOURS SSIEM 2024 Phénylcétonurie
BRIEF published on 09/02/2024 at 07:05, 1 year 6 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
PRESS RELEASE published on 09/02/2024 at 07:00, 1 year 6 months ago Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Relief Therapeutics announces interim results of PKU GOLIKE study at SSIEM 2024, showing potential benefits for phenylketonuria patients. Study evaluates overnight Phe fluctuations Clinical Trial Relief Therapeutics PKU GOLIKE SSIEM 2024 Phenylketonuria
BRIEF published on 08/30/2024 at 07:05, 1 year 6 months ago Relief Therapeutics publie ses résultats financiers du premier semestre 2024 et une mise à jour de l'entreprise Résultats Financiers Essais Cliniques Mise À Jour De L'entreprise Augmentation Des Revenus Réserves De Trésorerie
BRIEF published on 08/30/2024 at 07:05, 1 year 6 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Corporate Update Financial Results Revenue Increase Clinical Trials Corporate Update Cash Reserves
PRESS RELEASE published on 08/30/2024 at 07:00, 1 year 6 months ago Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update Relief Therapeutics reports half-year 2024 financial results and provides corporate update, showcasing operational progress, key development programs, and financial stability Half-year Results Relief Therapeutics Financial Update Development Programs Cash Reserves
BRIEF published on 08/05/2024 at 07:05, 1 year 7 months ago Relief Therapeutics Secures Up to $11 Million from Royalty Sales FDA Approval Clinical Development Relief Therapeutics Non-dilutive Funding Royalty Sales
Published on 03/27/2026 at 12:30, 1 hour 48 minutes ago Pasinex Closes First Tranche of Over-Subscribed Non-Brokered Private Placement
Published on 03/27/2026 at 12:00, 2 hours 18 minutes ago Temas Appoints Scientific Advisory Board to Accelerate RCL Commercialisation and Global Development
Published on 03/27/2026 at 11:00, 3 hours 18 minutes ago RE Royalties Announces Strategic Review to Evaluate Path for Long-Term Value Creation
Published on 03/27/2026 at 09:30, 4 hours 48 minutes ago Amap Street Stars Launches Macao Authentic Delicacies Ranking to Drive Cultural-Tourism Innovation in the Greater Bay Area
Published on 03/27/2026 at 13:30, 48 minutes ago Weiqiao Pioneering Group Adds Sixth National 'Green Factory'
Published on 03/27/2026 at 13:30, 48 minutes ago Weiqiao Chuangye : le groupe compte désormais six sites labellisés « usine verte » nationale
Published on 03/27/2026 at 13:00, 1 hour 18 minutes ago NR21: Mise à disposition du Rapport financier annuel 2025
Published on 03/27/2026 at 11:45, 2 hours 33 minutes ago Second National Showcase of Outstanding Works from China’s Rare Operatic Genres Held
Published on 03/27/2026 at 07:00, 7 hours 18 minutes ago WEB SA - CONVOCATION ASSEMBLEE GENERALE ORDINAIRE EXERCICE 2025 - 28/04/2026
Published on 03/26/2026 at 18:17, 20 hours 1 minute ago Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 20 hours 1 minute ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 20 hours 18 minutes ago Arrêté des comptes au 31 décembre 2025 et perspectives 2026
